Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosis

Livia Stanger(University of Michigan), Michael Holinstat(Thomas Jefferson University), Björn Dahlöf(Sahlgrenska University Hospital), Sylviane Lambert(University of Michigan), Niklas Bergh(Sahlgrenska University Hospital), P. Yalavarthi(University of Michigan), Atsumi Yamaguchi(University of Michigan)

European Heart Journal

November 1, 2023

10.1093/eurheartj/ehad655.2856

Cited by 0

Related Papers

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial

|The Lancet|1998|5.8k

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

|The Lancet|2005|2.9k

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|1.6k

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

|The Lancet|2010|518

An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis

|Cell|2024|102